This is a renewal application for a multidisciplinary hematology training program at New York University School of Medicine which has been in existence for over 42 years. The program is designed to provide two- year research opportunities for 5-6 post-doctoral fellows under the guidance of a faculty of 13 mentors. The training faculty consists of academic hematologists and hematopathologists with active laboratories applying basic science methods to the study of hematologic disorders as well as mentors of the basic science departments of NYU School of Medicine. There is abundant interaction among the faculty members within the program as well as with other scientists at this institution. The clinical research at this institution has been recognized by the NIH in its designation as a Comprehensive Cancer Center and an AIDS Center. The program director's research spans both areas. New faculty members have strengthened the basic science orientation of the program. The faculty works with this framework to train physician-scientists for future work in the academic community. A common theme of all the projects is their orientation to human disease.
These aims will be accomplished by training promising candidates in the design, execution and evaluation of experiments so that they may join the ranks of academic physician-scientists in basic as well as translational hematology research.
As the Nation's population is aging, it is becomes even more necessary that we train physician-scientists in hematologic disorders in basic and translational research. The training program at NYU School of Medicine will continue that mission.
|Raetz, Elizabeth A; Morrison, Debra; Romanos-Sirakis, Eleny et al. (2014) A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leu J Pediatr Hematol Oncol 36:458-63|
|Xing, Weiman; Busino, Luca; Hinds, Thomas R et al. (2013) SCF(FBXL3) ubiquitin ligase targets cryptochromes at their cofactor pocket. Nature 496:64-8|
|Busino, Luca; Millman, Scott E; Scotto, Luigi et al. (2012) Fbxw7?- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol 14:375-85|
|Ge, Sheng; Skaar, Jeffrey R; Pagano, Michele (2009) APC/C- and Mad2-mediated degradation of Cdc20 during spindle checkpoint activation. Cell Cycle 8:167-71|
|Sewak, Sanjeev; Sorich, Joan; O'Leary, James (2006) Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen. Anticancer Drugs 17:571-9|
|Pavlick, Anna C; Adams, Sylvia; Fink, Matthew A et al. (2003) Novel therapeutic agents under investigation for malignant melanoma. Expert Opin Investig Drugs 12:1545-58|
|Afonja, O; Smith Jr, J E; Cheng, D M et al. (2000) MEIS1 and HOXA7 genes in human acute myeloid leukemia. Leuk Res 24:849-55|
|Afonja, O; Amorosi, E; Ashman, L et al. (1998) Multilineage involvement and erythropoietin-"independent" erythroid progenitor cells in a patient with systemic mastocytosis. Ann Hematol 77:183-6|
|Smith, J E; Afonja, O; Yee, H T et al. (1997) Chromosomal mapping to 15q14 and expression analysis of the human MEIS2 homeobox gene. Mamm Genome 8:951-2|
|Jacobson, D R; Mills, N E (1994) A highly sensitive assay for mutant ras genes and its application to the study of presentation and relapse genotypes in acute leukemia. Oncogene 9:553-63|
Showing the most recent 10 out of 16 publications